INVO Bioscience Reports Third Quarter 2020 Financial Results

SARASOTA, Fla., Nov. 16, 2020 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal Culture System, today announced financial results for the quarter ended September 30, 2020.

Recent Highlights

    --  Revenues of $336,071 in the third quarter of 2020 increased 37%
        sequentially and 11% compared to the year ago quarter.
    --  Effective November 13, 2020, shares of the Company's common stock began
        trading on the Nasdaq Capital Market.
    --  Established a joint venture to operate dedicated INVOcell fertility
        clinics in Mexico.
    --  Submitted a 510k with the U.S. Food and Drug Administration (FDA) for
        5-day label expansion utilizing the retrospective data made available
        earlier this year.
    --  Strengthened the board with the addition of independent directors
        Barbara Ryan, Matthew Szot and Jeffrey J. Segal, M.D.
    --  Ended the quarter, September 30, 2020, with a cash position of
        approximately $0.9 million. In November 2020, the Company announced the
        execution of an underwriting agreement with Roth Capital Partners for an
        underwritten public offering of 3,625,000 shares of its common stock at
        a public offering price of $3.20 per share for expected total gross
        proceeds of $11.6 million. The offering is expected to close on November
        17, 2020.
    --  Net loss for the third quarter totaled $(1.77) million, which included
        $(837,236) of non-cash charges primarily related to the debt discount
        amortization and stock-based compensation. Adjusted EBITDA for the third
        quarter period was $(934,788).

Management Discussion

"Sales during the third quarter ended September 30, 2020 increased 37% sequentially over the quarter ended June 30, 2020, driven by higher sales in the United States as our partner Ferring placed additional orders toward the required annual minimum," commented Steve Shum, Chief Executive Officer of INVO Bioscience. "Although the market for fertility treatment services has been affected by COVID-19 this year, we have utilized this period to put in place what we believe are the necessary and important building blocks to create an organization well positioned to rapidly expand the adoption of the INVOcell solution, and we are starting to recognize the benefit of this work. In our opinion, the additional retrospective data made available this year, which represented the second year of available INVOcell usage data, provides a critically important element for our commercialization efforts."

"One of our most recent developments included the signing of our second joint venture agreement to open dedicated INVO clinics, this one in Mexico with Dr. Francisco Arredondo and Dr. Ramiro Ramirez. Dr. Arredondo was one of the early adopters of the INVOcell solution while practicing in the United States. We continue to engage in active discussions with additional partners in many of the major fertility markets for both distribution agreements and joint-venture concepts."

"We also took what we believe were critical and necessary actions to strengthen the Company operationally, financially and functionally which we believe positions us well to execute on our initiatives. These included the hiring of highly accomplished industry individuals to drive the commercialization efforts; the raising of capital required to fund our key commercial and development programs; the appointment of independent board members to meet corporate governance requirements; and the listing of the Company on the Nasdaq. With our strengthened balance sheet, we believe we have the tools, infrastructure and people now in place to drive long-term adoption of INVOcell, grow revenue, achieve profitability and drive shareholder value," concluded Mr. Shum.

Market Update

    --  United States: We continue to focus our U.S. efforts on supporting our
        partner, Ferring, and establishing certain INVO clinics in accordance
        with our agreement. Although the effort to develop INVO clinics has
        taken longer than we originally envisioned, we believe we are making
        excellent progress and expect to provide updates near-term.
    --  Mexico: In September 2020, INVO Bioscience created a joint venture with
        Dr. Francisco Arredondo, MD MPH, a respected and experienced board
        certified reproductive endocrinologist, and Dr. Ramiro Ramirez, MD, a
        physician and owner of several successful enterprises in Mexico, focused
        on developing the Mexico market for INVOcell. Dr. Arredondo was an early
        adopter of the INVOcell solution as he began offering IVC via the
        INVOcell to his patients at fertility clinics in San Antonio and Austin
        in 2016. In 2017, due to the initial success in expanding the
        accessibility of infertility treatment to patients utilizing INVOcell,
        he decided to open a center where he would exclusively offer the
        INVOcell solution in McAllen, Texas. The new jointly owned operation is
        targeting to open the initial center in the city of Monterrey, Mexico in
        early 2021.
    --  India: INVO Biosciences' JV partnership, signed in January 2020, is
        focused on opening dedicated INVO-only clinics in the India marketplace.
        While these efforts have and continue to be delayed due to the pandemic
        and the various lockdowns, the joint-venture's revised target for
        establishing the first clinic is now first quarter of 2021.
    --  Africa and Eurasia: The Company previously executed distribution
        agreements in certain markets in Africa and Eurasia toward the end of
        2019. Following execution of those agreements, the Company began the
        product registration and approval process in order to begin importing
        into those markets. The Company has received the first of the product
        registration approvals for Turkey and Jordan and is now working with
        those distribution partners to begin training and commercialization
        activities. Work is continuing with the remaining countries to complete
    --  New Markets: INVO Bioscience is targeting a number of additional markets
        outside the U.S. (OUS) and has discussions underway in Canada, Columbia,
        Spain, Macedonia, Indonesia, Russia, Malaysia, and China among others.
        The Company is maintaining its goal of adding additional OUS markets
        through distribution or partnerships before year end.

Clinical/Regulatory Update

The Company continues to advance its 5-day label expansion efforts. The clinical trial, which previously received IRB approval to begin recruitment, and was placed on hold earlier this year due to the pandemic, should be ready to resume shortly. Separately, a 510(k) application utilizing real world data to support label expansion was submitted and is now pending with the FDA. The Company received a request for additional information from the FDA and is preparing its response to those questions, expected to be submitted in January 2021.

Financial Results

Revenue for the three months ended September 30, 2020, was $336,071 compared to $303,571 for the same three-month period in 2019, an increase of 11%, and compared to $246,072 in the second quarter of 2020 ended June 30, 2020, an increase of 37%.

The gross margin reported for the three months ended September 30, 2020 was 92% compared to 85% for the three months ended September 30, 2019.

Selling, general and administrative expenses for the three months ended September 30, 2020 were $1,463,887 compared to $891,008 for the three months ended September 30, 2019. The increase of $572,879 or 64%, in the third quarter of 2020 was primarily the result of an increase in personnel expenses, stock-based compensation and other corporate expenses.

We began to fund additional research and development ("R&D") efforts in 2020 in order to support our 5-day label expansion efforts, and additional patent filings. R&D expenses were $112,552 for the three months ended September 30, 2020. During the same period in 2019 we did not fund any R&D activity.

During the three months ended September 30, 2020, we incurred $504,061 in interest expense, compared to $47,462 in the three months period ended September 30, 2019. The increase of $456,599 or approximately 962% was primarily due to the increase in the amortization of the debt discount, debt issuance cost and interest on the 2020 Convertible Notes.

We reported a net loss of $1,771,827 for the three months ended September 30, 2020, compared to a net loss of $710,334 for the three months ended September 30, 2019. The increase of $1,061,493 or approximately 149%, is primarily due to an increase in operating expense, interest expenses and financing fees. Total non-cash related expenses in the period totaled $837,236, primarily associated with the debt amortization and equity-based expensing.

The Company ended the quarter ended September 30, 2020 with a cash position of approximately $0.9 million. In November 2020, the Company announced of its execution of an underwriting agreement with Roth Capital Partners for an underwritten public offering of 3,625,000 shares of its common stock at a public offering price of $3.20 per share. Upon closing of the offering, the gross proceeds to INVO Bioscience from this offering are expected to be $11.6 million.

Conference Call Details

INVO Bioscience has scheduled a conference call for Thursday, November 19, 2020, at 4:30 pm ET (1:30 pm PT) to review these results and recent events. Interested parties can access the conference call by dialing (877) 270-2148 or (412) 902-6510 or can listen via a live Internet webcast at, which is also available in the Investor Relations section of the Company's website at

If you would like to submit a question to be addressed on the call, please email

A teleconference replay of the call will be available for seven days at (877) 344-7529 or (412) 317-0088, confirmation #10150131. A webcast replay will be available in the Investor Relations section of the Company's website at for 30 days.

About INVO Bioscience

INVO Bioscience, Inc. (Nasdaq: INVO) is an innovative medical device company developing solutions for the global infertility industry. INVO's goal is to increase access to care and expand fertility treatment across the globe while seeking to lower the cost and increase the availability of care. INVO's lead commercial product, the INVOcell, is a patented Assisted Reproductive Technology (ART) used in the treatment of infertility. The INVOcell device and procedure is unique as the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development. As an alternative to traditional in Vitro Fertilization (IVF), the revolutionary in vivo method of vaginal incubation offers patients a more natural and intimate experience. INVO Bioscience is headquartered in Sarasota, FL. For more information, please visit

Safe Harbor Statement

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.


                                                                                                                                        September 30,                       December 31,

                                                                                                                                                 2020                                2019

         ASSETS                                                                                                                    (unaudited)                         (unaudited)

         Current assets

         Cash                                                                                                                                          $
          908,289                   $

         Accounts receivable                                                                                                                                     3,699                                7,558

         Inventory                                                                                                                                             241,484                              101,387

         Prepaid expenses and other current assets                                                                                                             218,667                              195,910

         Total current assets                                                                                                                                1,372,139                            1,543,440

         Property and equipment, net of depreciation of $49,730 and $42,147 respectively                                                                       106,000                               93,055

         Other assets:

         Capitalized patents, net of amortization of $71,843 and $70,488 respectively                                                                            5,879                                7,234

         Lease right of use                                                                                                                                     84,953                              101,883

         Trademarks                                                                                                                                             87,347                               49,867

         Investment in joint ventures                                                                                                                           32,674

         Total other assets                                                                                                                                    210,853                              158,984

         Total assets                                                                                                                                $
          1,688,992                   $


         Current liabilities

         Accounts payable and accrued liabilities, including related parties                                                                           $
          455,978                     $

         Accrued compensation - related party                                                                                                                  532,592                              393,017

         Deferred revenue, current portion                                                                                                                     714,286                              714,286

         Current portion of lease liability                                                                                                                     22,356                               21,365

         Notes payable                                                                                                                                         157,620

         Income taxes payable                                                                                                                                                                          912

         Total current liabilities                                                                                                                           1,882,832                            1,501,110

         Lease liability, net of current portion                                                                                                                64,436                               81,494

         Deferred revenue, net of current portion                                                                                                            3,035,714                            3,571,429

         Convertible notes, net of discount of $3,008,258 and $174,310 respectively                                                                            607,521                              325,784

         Convertible notes - related party, net of discount of $0 and $17,151 respectively                                                                                                          28,824

         Deferred tax liability                                                                                                                                    433                                  433

         Total liabilities                                                                                                                                   5,590,936                            5,509,074

         Stockholders' deficiency

         Preferred Stock, $.0001 par value; 100,000,000 shares authorized; No shares
      issued and outstanding as of September 30, 2020 and December 31, 2019,

         Common Stock, $.0001 par value; 200,000,000 shares authorized;                                                                                            495                                  489
      4,953,910 and 4,884,879 issued and outstanding as of September
      30, 2020 and December 31, 2019, respectively

         Additional paid-in capital                                                                                                                         24,525,427                           20,174,682

         Accumulated deficit                                                                                                                              (28,427,866)                        (23,888,766)

         Total stockholders' deficiency                                                                                                                    (3,901,944)                         (3,713,595)

         Total liabilities and stockholders' deficiency                                                                                              $
          1,688,992                   $


                                                            For the Three                                      For the Three                                      For the Nine           For the Nine

                                                            Months Ended                                       Months Ended                                       Months Ended           Months Ended

                                                            September 30,                                      September 30,                                      September 30,          September 30,

                                                                     2020                                                2019                                                2020                    2019


              Product revenue                                               $
          157,500                                                        $
        125,000                     $
             305,000       $

              License revenue                                                       178,571                                                              178,571                                535,714                 535,714

              Total Revenue                                                         336,071                                                              303,571                                840,714               1,151,641

              Cost of Goods Sold                                                     27,398                                                               44,926                                 78,562                 111,186

              Gross Margin                                                          308,673                                                              258,645                                762,152               1,040,455

              Research and development                                              112,552                                                                                                    177,492

              Selling, general and administrative expenses                        1,463,887                                                              891,008                              4,311,872               2,087,725

              Total operating expenses                                            1,576,439                                                              891,008                              4,489,364               2,087,725

              Loss from operations                                              (1,267,766)                                                           (632,363)                           (3,727,212)            (1,047,270)

              Interest expense                                                      504,061                                                               47,462                                811,888                 332,677

              Total other expenses                                                  504,061                                                               47,462                                811,888                 332,677

              Loss before income taxes                                          (1,771,827)                                                           (679,825)                           (4,539,100)            (1,379,947)

              Provision for income taxes                                                                                                               (30,509)                                                     (30,509)

              Net Loss                                                   $
         (1,771,827)                                                     $
        (710,334)                  $
           (4,539,100)    $

              Basic net loss per weighted average shares                     $
          (0.36)                                                        $
        (0.15)                     $
             (0.92)       $
    of common stock

              Diluted net loss per weighted average                          $
          (0.36)                                                        $
        (0.15)                     $
             (0.92)       $
    shares of common stock

              Basic weighted average number of shares                             4,946,125                                                            4,861,377                              4,932,405               4,847,074
    of common stock

              Diluted weighted average number of                                  4,946,125                                                            4,861,377                              4,932,405               4,847,074
    shares of common stock

                  Adjusted EBITDA

                                                                            Three Months Ended             
     Nine Months Ended

        September 30                                    
     September 30

                                                                                                      2020                                               2020

     Net Loss                                                                              $(1,771,827)                                      $(4,539,100)


           Interest Expense                                                              88,963                                            133,845

           Provision for Income taxes

           Stock-based compensation                                                      74,201                                            480,975

           Stock Option expense                                                         255,797                                            852,187

           Amortization of Debt discount                                                415,098                                            678,043

           Depreciation and amortization                                                  2,980                                              8,938

             Adjusted EBITDA*                                                              $(934,788)                                      $(2,385,112)


             *Adjusted to also include non-cash, stock-based expensing

View original content to download multimedia:

SOURCE INVO Bioscience, Inc.